No Data
No Data
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Most Shareholders Will Probably Agree With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) CEO Compensation
Key Insights Tarsus Pharmaceuticals' Annual General Meeting to take place on 13th of June Salary of US$619.5k is part of CEO Bobby Azamian's total remuneration The overall pay is 49% below the ind
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Tarsus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Tarsus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Tarsus Pharmaceuticals (TARS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $57.00 to $61.00.
HC Wainwright & Co. : Tarsus Pharmaceuticals (TARS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $57.00 to $61.00.
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $61
HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $57 to $61.